WeChat and WhatsApp： +85269492373

Retatrutide (LY3437943) acetate is a triple agonist peptide for the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R).

Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643, and 0.775 nM, respectively. It exhibits activity on mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191, and 0.794 nM, respectively.

In vivo, Retatrutide (LY3437943) acetate engages with GCGR and enhances glucose tolerance in an ipGTT by acting through GIP or GLP-1 receptors. Activation via the glucagon receptor by Retatrutide acetate leads to significant weight reduction and increased energy expenditure. Retatrutide acetate can be utilized in research related to obesity.

Retatrutide, LY3437943

CAS#: 2381089-83-2

Molecular Formula: C221H342N46O68

Molecular Weight: 4731.33

Sequence: H-Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-α-Me-Leu-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2

Appearance: White Powder

Purity (HPLC): ≥99.0%

Single Impurity (HPLC): ≤1.0%

Sodium Content (HPLC): 5.0%-12.0%

Moisture Content (Karl Fischer): ≤10.0%

Peptide Content: ≥80.0%

Storage: Store at 2-8 degrees Celsius in a dry and cool place.

Packaging: 1g-1kg, plastic bottle

Intended Use: For scientific research purposes

What is Retatrutide?

Retatrutide (LY-3437943) is a drug in development to treat obesity and type 2 diabetes. This active compound activates receptor agonists in our bodies, helping with blood sugar control and weight loss management. Retatrutide is a glucagon-like peptide-1 (GLP-1) agonist, a new drug that also acts on another hormone called glucose-dependent insulnotropic polypeptide (GIP). These two hormones combined work wonders in promoting weight loss. But Retatrutide goes one step further; the drug also acts as a third hormone: glucagon.

Product Pictures